- EBITA Results: Sobi’s first quarter EBITA was SEK 2.26 billion, falling short of the expected SEK 2.29 billion.
- EBITA Margin: The EBITA margin was 35%, below the estimate of 36.3%.
- Total Revenue: Sobi reported revenue of SEK 6.47 billion, surpassing the expected SEK 6.33 billion.
- Elocta Performance: Elocta generated revenue of SEK 1.27 billion, outperforming the estimate of SEK 1.11 billion.
- Alprolix Revenue: Alprolix fell short with SEK 581 million in revenue, compared to an estimate of SEK 637.3 million.
- Kineret Sales: Kineret revenue came in at SEK 735 million, exceeding the estimate of SEK 715.8 million.
- Orfadin Performance: Orfadin revenue was slightly above estimates at SEK 110 million versus SEK 108.6 million.
- Synagis Revenue Shortfall: Synagis only secured SEK 21 million in revenue, missing the SEK 60.6 million estimate.
- Gamifant Success: Gamifant achieved SEK 582 million in revenue, outpacing the estimated SEK 504.7 million.
- Adjusted EBIT: The adjusted EBIT was SEK 1.45 billion, lower than the expected SEK 1.8 billion.
- Analyst Recommendations: There are 12 buy, 3 hold, and 1 sell recommendations for Sobi.
A look at Swedish Orphan Biovitrum AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Swedish Orphan Biovitrum AB (SOBI), a bio-pharmaceutical and bio-technology company known for developing therapies for various medical conditions, has received a notably positive long-term outlook based on Smartkarma Smart Scores. The company scored high marks in Growth and Resilience, showcasing a promising future in terms of expansion and stability in the industry. This indicates that SOBI is well-positioned to continue its growth trajectory and weather uncertainties effectively.
Although the company scored lower in Dividend, indicating lower returns for investors seeking income, its overall outlook remains positive. With solid scores in Value and Momentum as well, Swedish Orphan Biovitrum AB demonstrates a strong competitive standing in the market. Investors looking for growth opportunities in the bio-pharmaceutical sector may find SOBI a compelling choice for their long-term portfolios.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
